| Brochure | Award Nomination Form | Registration Form

      PLATINUM PARTNER                PRINCIPAL SPONSOR              
                                                                          

KNOWLEDGE PARTNER                                                                                                                                                       MEDIA PARTNERS   
                                                                                                         
 

SUPPORTERS 
                                                                                                

                                                                                               
                 



India is a leader in global generic pharmaceuticals manufacturing. It supplies 20% of global generic drugs and is a preferred location for generic drug production. In FY 2016, India exported pharmaceutical products worth USD 16.89 billion, with the number expected to reach USD 40 billion by 2020. The country’s pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015‐20 to reach USD 55 billion.

The industry attracted 4.48% of the total FDIs into India from April 2000 to December 2016. The cumulative FDI inflows worth USD 14.53 billion were made during the same period.

Although India has strong position in the production of generic pharmaceutical medicines but has not yet realized it’s potential to develop a strong, research based pharmaceutical industry that can produce innovative medicines. India has an opportunity to build on its strengths in generics and move up the value chain by enabling innovations and new drug discovery. However, the Indian pharmaceutical industry does not have a strong track record of innovation. A comparison of India with established pharmaceutical innovation leaders‐the US, UK and Japan with countries that have recently moved up the innovation ladder‐South Korea, China and Singapore – shows that there are multiple gaps in the Indian ecosystem. India invests just 0.9% of its GDP (Gross Domestic Product) towards overall research and development compared to an investment of 1.6% in the UK, 1.9% in China, 2.8% in the US and 3.3% and 4% in Japan and South Korea respectively. Availability of funding and overall investments are key concerns that should be discussed.

India is not short on intention and has started to recognize the need to develop an enabling ecosystem that supports investment, technology transfer and growth in innovative areas such as biosciences. However, India needs to undertake multiple initiatives across infrastructure, financing, human resources and the legal and regulatory framework to find a place as a preferred destination for pharmaceutical innovation.

To address this subject matter of importance, ASSOCHAM is organizing “Pharma Conclave 2018: Strengthening Indian Pharmaceutical Industry through R&D and Innovation on May 9, 2018 at Hotel The Imperial, New Delhi.

Registration Fees: 

  • Per Delegate: Rs. 3,000/‐  
  • GST will be applicable @ 18%: